Precigen Inc (OQ:PGEN)

Business Focus: Biotechnology & Medical Research

May 15, 2020 07:30 am ET
Precigen to Present Preclinical Data for PRGN-3005 UltraCAR-T™ at the AACR Virtual Annual Meeting II in June 2020
GERMANTOWN, Md., May 15, 2020 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced preclinical data for its innovative investigational PRGN-3005 UltraCAR-T™ in patients with advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer will be presented as an e-poster at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, to be held from June 22-24, 2020. The e-poster presentation titled PRGN-3005 UltraCAR-T: M...
May 06, 2020 04:05 pm ET
Precigen Reports First Quarter 2020 Financial Results
GERMANTOWN, Md., May 6, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter financial results for 2020. ...
Apr 29, 2020 07:30 am ET
Precigen to Announce First Quarter 2020 Financial Results on May 6th
GERMANTOWN, Md., April 29, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release first quarter 2020 financial results after the market closes on Wednesday, May 6th, 2020.  The Company will host a conference call that day at 4:15 pm ET to discuss the results and provide a general business update....
Apr 20, 2020 07:36 am ET
Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors
GERMANTOWN, Md., April 20, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase I/II trial for Precigen's PRGN-2009, a first-in-class, off-the-shelf (OTS) investigational immunotherapy utilizing the AdenoVerse™ platform designed to activate the immune system to recognize and target HPV+ solid tumors. HPV+ cancers represent ...